ATE549011T1 - Formulierungen mit verzögerter freisetzung, die somatostatin-analoge wachstumshormoninhibitoren enthalten - Google Patents
Formulierungen mit verzögerter freisetzung, die somatostatin-analoge wachstumshormoninhibitoren enthaltenInfo
- Publication number
- ATE549011T1 ATE549011T1 AT05077559T AT05077559T ATE549011T1 AT E549011 T1 ATE549011 T1 AT E549011T1 AT 05077559 T AT05077559 T AT 05077559T AT 05077559 T AT05077559 T AT 05077559T AT E549011 T1 ATE549011 T1 AT E549011T1
- Authority
- AT
- Austria
- Prior art keywords
- growth hormone
- somatostatin analogue
- sustained release
- release formulations
- formulations containing
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 3
- 108010051696 Growth Hormone Proteins 0.000 title abstract 3
- 239000000122 growth hormone Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 3
- 229940075620 somatostatin analogue Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 abstract 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 1
- 108010016076 Octreotide Proteins 0.000 abstract 1
- -1 alkyl fatty acid ester Chemical class 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960002700 octreotide Drugs 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05077559A EP1787658B1 (de) | 2005-11-10 | 2005-11-10 | Formulierungen mit verzögerter Freisetzung, die Somatostatin-analoge Wachstumshormoninhibitoren enthalten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE549011T1 true ATE549011T1 (de) | 2012-03-15 |
Family
ID=35840709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05077559T ATE549011T1 (de) | 2005-11-10 | 2005-11-10 | Formulierungen mit verzögerter freisetzung, die somatostatin-analoge wachstumshormoninhibitoren enthalten |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1787658B1 (de) |
| AT (1) | ATE549011T1 (de) |
| CY (1) | CY1112857T1 (de) |
| DK (1) | DK1787658T3 (de) |
| ES (1) | ES2383303T3 (de) |
| PL (1) | PL1787658T3 (de) |
| PT (1) | PT1787658E (de) |
| SI (1) | SI1787658T1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
| PL2225271T3 (pl) * | 2007-12-03 | 2013-12-31 | Italfarmaco Spa | Nowe nieselektywne analogi somatostatyny |
| ITUB20160416A1 (it) * | 2016-01-28 | 2017-07-28 | Italfarmaco Spa | Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3045135A1 (de) | 1980-11-29 | 1982-06-09 | Sandoz-Patent-GmbH, 7850 Lörrach | Pharmazeutische kompositionen enthaltende bioabbaubare polymere |
| FR2537980B1 (fr) | 1982-12-17 | 1986-12-19 | Sandoz Sa | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation |
| GB8318552D0 (en) | 1983-07-08 | 1983-08-10 | Sandoz Ltd | Organic compounds |
| HU198626B (en) | 1986-05-27 | 1989-11-28 | Sandoz Ag | Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient |
| GB2193891B (en) | 1986-08-18 | 1990-07-25 | Sandoz Ltd | Nasal pharmaceutical composition containing a somatostatin anologue. |
| HU906340D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| DE3822557C2 (de) | 1987-07-10 | 1998-07-02 | Ciba Geigy Ag | Arzneimittel, enthaltend Somatostatine |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| MY108621A (en) | 1990-08-01 | 1996-10-31 | Novartis Ag | Polylactide preparation and purification |
| GB9206736D0 (en) | 1992-03-27 | 1992-05-13 | Sandoz Ltd | Improvements of organic compounds and their use in pharmaceutical compositions |
| SI9300468A (en) | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| WO1994008610A1 (en) | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Pharmaceutical emulsion compositions |
| WO1995000126A1 (en) | 1993-06-22 | 1995-01-05 | Sandoz Ltd. | Surface-modified albumin microspheres and pharmaceutical compositions containing them |
| IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| DE69719320T2 (de) | 1996-06-11 | 2003-12-11 | Novartis Ag, Basel | Kombination eines somatostatin analogs und eines rapamycins |
| EP0839525B1 (de) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Zubereitung mit verzögerter Freisetzung |
| AU1198599A (en) * | 1997-10-24 | 1999-05-17 | Neorx Corporation | Delivery vehicles for bioactive agents and uses thereof |
| GB2331924A (en) | 1997-12-08 | 1999-06-09 | Phares Pharm Res Nv | Lipid compositions and their use |
| ATE260674T1 (de) * | 1998-08-17 | 2004-03-15 | Pfizer Prod Inc | Stabilisierte proteinzusammensetzung |
| US6159935A (en) | 1999-11-29 | 2000-12-12 | Pharmacia & Upjohn Co. | Method for preventing diarrhea |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| AU2001283957A1 (en) | 2000-07-27 | 2002-02-13 | Novartis Ag | Treatment of ocular disorders with somatostatin analogues |
| US20030049320A1 (en) * | 2000-12-18 | 2003-03-13 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
| WO2003089008A1 (en) | 2002-04-19 | 2003-10-30 | Novartis Ag | Novel biomaterials, their preparation and use |
| US20040097419A1 (en) | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| GB0228571D0 (en) | 2002-12-06 | 2003-01-15 | Novartis Ag | Organic compounds |
-
2005
- 2005-11-10 AT AT05077559T patent/ATE549011T1/de active
- 2005-11-10 PT PT05077559T patent/PT1787658E/pt unknown
- 2005-11-10 SI SI200531534T patent/SI1787658T1/sl unknown
- 2005-11-10 ES ES05077559T patent/ES2383303T3/es not_active Expired - Lifetime
- 2005-11-10 PL PL05077559T patent/PL1787658T3/pl unknown
- 2005-11-10 EP EP05077559A patent/EP1787658B1/de not_active Expired - Lifetime
- 2005-11-10 DK DK05077559.2T patent/DK1787658T3/da active
-
2012
- 2012-06-11 CY CY20121100528T patent/CY1112857T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1787658B1 (de) | 2012-03-14 |
| PT1787658E (pt) | 2012-06-22 |
| DK1787658T3 (da) | 2012-06-25 |
| CY1112857T1 (el) | 2016-04-13 |
| ES2383303T3 (es) | 2012-06-20 |
| PL1787658T3 (pl) | 2012-08-31 |
| SI1787658T1 (sl) | 2012-07-31 |
| EP1787658A1 (de) | 2007-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2195798T1 (es) | Formulacion para mujeres menopausicas. | |
| CY1112333T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει μια δραστικη ουσια πανω σε μια μητρα | |
| ATE216230T1 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
| UY25148A1 (es) | Método para producir una composición farmacéutica que comprende un análogo de ácido gama aminobutírico (gaba) y una droga antiinflamatoria no esteroide (nsaid) | |
| ATE279209T1 (de) | Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride | |
| ES2185625T3 (es) | Formulacion farmaceutica estabilizada que incluye hormona de crecimiento e histidina. | |
| JP2003534265A5 (de) | ||
| ATE394365T1 (de) | Verfahren zur synthese von verbindungen vom ceramidtyp | |
| WO2003013497A1 (en) | Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction | |
| ATE413865T1 (de) | Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür | |
| BR0209320A (pt) | ésteres de uridina farmaceuticamente ativos | |
| AR029615A1 (es) | Una formulacion farmaceutica para la administracion oral | |
| CL2011001225A1 (es) | Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros. | |
| WO2008093772A1 (ja) | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 | |
| PE20040158A1 (es) | Sales de nateglinida | |
| CY1112857T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης αναλογου σωματοστατινης αναστολεων αναπτυξης ορμονης | |
| GEP20053455B (en) | Pharmaceutical Preparations | |
| PE20011223A1 (es) | Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico | |
| AR029412A1 (es) | Forma cristalina | |
| FR2722410B1 (fr) | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique | |
| NO20024796L (no) | Preparater for anvendelse som penetrasjonsfremmere i transdermale formuleringer for meget lipofile aktive bestanddeler | |
| DE60004191D1 (de) | Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung | |
| JP5048372B2 (ja) | 育毛促進剤 | |
| WO2006065886A3 (en) | Pest control compositions, and methods and products utilizing same | |
| CA2494503A1 (en) | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |